No Detail Found!

The mouse model of hepatic veno-occlusive disease

Author(s)
Licai An Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Xijing Li Department of Pathology, Yantaishan Hospital,Yantai,China
Xiaoxia Chu Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Xiaoqian Liu Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Yuanfeng Zhang Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Yanming Wang Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Yan Wang Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Yinghui Liu Department of Hematology, Yantai Yuhuangding Hospital,Yantai,China
Abstract
With the application of hematopoietic stem cell transplantation, Subacute or acute increase in the incidence of hepatic veno-occlusive disease (HVOD) becomes more common and it can lead to fatal complications. This article characterizes a mouse model of HVOD induced by monocrotaline. After gavage with monocrotaline was performed on BALB/c mice, On the 3rd, 4th, 6th, 8th and 10th days, mice were anesthetized, blood was collected and the liver was removed. Liver slices were processed by HE stain, Masson's trichrome stain or immunohistochemical stain. From days 3 through 4, histopathology and cytokine changes were determined as severe, early HVOD. From days 6 through 8, the changes were considered to represent late HVOD. On the 10th day, the above changes showed that late HVOD gradually improved.
Publication Details
Page(s) 2391-2400
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S6, Year: 2021

Request the full text from PASTIC

Keywords
liver function, fibrosis, Animal Model, inflammatory cytokines, endothelial cell
References
Borowska H,Aieiszewska E,Czaudema P,Sawicki B .2004 .Daetinomycin-induced veno-oeclusive diseaseinrats.The hepatoproteetive action of amifostine. Evaluation in a light and eleetron microseope. Folia Morph-ologiea. , 63(1) : 91-93.
Boué J,Basso L,Cenac N,Blanpied C,Rolli-Derkinderen M,Neunlist M,Vergnolle N,Coppell JA,Richardson PG,Soiffer R,Martin PL,Kernan NA,Chen A,Guinan E,Vogelsang G,Krishnan A,Giralt S,Revta C,Carreau NA,Iacobelli M,Carreras E,Ruutu T,Barbui T,Antin JH,Niederwieser D .2010 .Hepatic VenoOcclusive Disease following Stem Cell Transplantation: Incidence, Clinical Course and Outcome. Biol. Blood Marrow Transplant, 16(2) : 157-168.
Carreras E .2000 .Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur. J. Haematol., 64(5) : 281-291.
Carson RT,Vignali DA .1999 .Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods., 227(1-2) : 41-52.
Chen MY,Cai JT,Du Q,Wang LJ,Chen JM,Shao LM JM .2008 .Reliable experimental model of hepatic veno-occlusive disease caused by monocrotaline. Hepatobiliary Pancreat Dis. lnt., 7(4) : 395-400.
Chen Z,Huo JR,Yang L,Zhu HY .2011 .Effect of ligustrazine on mouse model of hepatic veno-occlusive disease induced by Gynura segetum. J. Gastroenterol Hepatol, 26(6) : 1016-1021.
Coppell JA,Brown SA,Perry DJ SA .2003 .Veno occlusive disease: Cytokines, genetics and haemostasis. Blood Rev, 17(2) : 63-70.
Corbacioglu S,Carreras E,Mohty M,Pagliuca A,Ballabio M,Hume R,Bandiera V,Finetto G,Richardson PG .2015 .Defibrotide for the treatment of hepatic veno-occlusive disease:an update from the international compassionate use program in 710 patients. Blood Marrow Transplant, 21(2) : S108-S108.
DeLeve LD .1996 .Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology, 24(4) : 830-837.
Deleve LD,Mccuskey RS,Wang XD,Hu L,McCuskey MK,Epstein RB,Kanel GC .1999 .Characterization of a reproducible rat model of hepatic veno occclusive disease. Hepatology, 29(6) : 1779-1793.
Diehl AM .2002 .Liver regeneration. , 7 : e301-e314.
Dietrich G .2014 .Endogenous regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice. Gastroenterology, 146(1) : 166-175.
Enric C,Marina DB,Laura RO,Carmen M,Francesc FA,Montserrat R .2011 .The incidence of venoocclusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol. Blood Marrow Transplant, 17(11) : 1713-1720.
Esmon CT .2004 .Crosstalk between inflammation and thrombosis. Maturitas, 47(4) : 305-314.
Fan CQ,Crawford JM .2014 .Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J. Clin. Exp, 4(4) : 332-346.
Faouzi S,Lepreux S,Bedin C,Dubuisson L,Balabaud C,Bioulac-Sage P,Desmoulière A,Rosenbaum J .1999 .Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest, 79(4) : 485-493.
Gorski JC,Wang Z,Haehner-Daniels BD,Wrighton SA,Hall SD .2000 .The effect of hormone replacement therapy of CYP3A activity. Clin. Phannacol, 68(4) : 412-417.
Gozdzik J,Krasowska-Kwiecień A,Wedrychowicz A .2008 .Sinusoidal obstruction disease (SOS), previous hepatic venoocclusive disease (VOD)--still serious complication after hematopoietic stem cell transplantation. Przegl Lek, 65(4) : 203.
Kalayoglu-Besisik S,Yenerel MN,Caliskan Y,Ozturk S,Besisik F,Sargin D F .2005 .Time related changes in the incidence, severity and clinical outcome of hepatic veno occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc., 37(5) : 2285-2289.
Knolle PA .2003 .Limmer A. Control of immune responses by savenger liver endothelial cells. Swiss Med Wkly, 133 : 501-506.
Lee SH,Yoo KH,Sung KW,Koo HH,Kwon YJ,Kwon MM,Park HJ,B-K P,Kim YY,Park JA .2010 .Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: Incidence, risk factors, and outcome. Bone Marrow Transplant, 45(8) : 1287-1293.
Marra F .2002 .Chemokines in liver inflammation and fibrosis. , 7 : d1899-d1914.
Pihusch V,Pihusch M,Penovici M,Kolb HJ,Hiller E,Pihusch R .2005 .Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb. Res, 116(3) : 233-240.
Mohty M,Malard F,Abecassis M,Aerts E,Alaskar A,Aljurf M,Arat M,Bader P,Baron F,Bazarbachi A .2015 .Sinusoidal obstruction syndrome/venoocclusive disease: Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 50(6) : 781-789.
Richardson P,Guinan E .2001 .Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta. Haematol, 106(1-2) : 57-68.
Richardson PG,Triplett BM,Ho VT,Chao N,Dignan FL,Maglio M,Mohty M .2018 .Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert. Rev. Clin. Pharmacol, 11(2) : 113-124.
Schildberg FA,Hegenbarth SI,Schumak B,Scholz K,Limmer A,Knolle PA .2008 .Liver sinusoidal endothelial cells veto CD8 T cell activation by antigenpresenting dendritic cells. Eur. J. Immunol., 38(4) : 957-967.
Tack DK,Letendre L,Kamath PS,Tefferi A .2001 .Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplantation, 28(9) : 895-897.
Tefferi A,Kumar S,Wolf RC,Lacy MQ,Inwards DJ,Gloor J M RC,Kamath PS,Litzow MR .2001 .Charcoal hemofiltration for hepatic venoocclusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 28 : 997-999.
Valla DC,Cazals-Hatem D .2016 .Sinusoidal obstruction syndrome. Clin. Res. Hepatol. Gastroenterol., 40(4) : 378-385.
Yang M,Ruan J,Fu PP,Lin G PP .2016 .Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloidinduced hepatotoxicity. Chem. Biol. Interact, 243 : 119-126.
Zeng L,An L,Fang T,Pan B,Sun H,Chen C,Cao J,Li Z,Xu K Z .2013 .A murine model of hepatic venoocclusive disease induced by allogeneic hematopoietic stem cell transplantation. Cell. Biochem. Biophys., 67(3) : 939-948.
0

Citations

0

Downloads

7

Views